Physician profile
Alexander Chun
NPI 1770592685
$17,838.95
in general payments reported to CMS, 2019-2025
43 companies · $3,271 in 2025
The $3,271 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,589 · 2020: $1,019 · 2021: $1,802 · 2022: $2,797 · 2023: $3,742 · 2024: $3,619 · 2025: $3,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Debt Forgiveness: $400 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,111.65 |
| Debt Forgiveness | $400.27 |
| Education | $120.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,634.62 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Gilead Sciences, INC. | $2,563.01 | 2019-2025 | Biktarvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,355.31 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Qol Medical, LLC | $1,474.04 | 2019-2025 | Sucraid, Sucraid |
| Viiv Healthcare Company | $1,077.59 | 2020-2025 | Dovato, Apretude, Cabenuva |
| Takeda Pharmaceuticals U.S.A., INC. | $794.68 | 2019-2025 | Entyvio, Gattex |
| Merck Sharp & Dohme LLC | $743.20 | 2019-2025 | Dificid, Delstrigo, Pifeltro |
| Novo Nordisk INC | $610.01 | 2020-2025 | Wegovy |
| Janssen Biotech, INC. | $606.01 | 2019-2025 | Tremfya, Symtuza, Stelara |
| Olympus America INC. | $400.27 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $328.46 | 2019-2025 | Farxiga, Breztri |
| Ardelyx, INC. | $326.92 | 2024-2025 | Ibsrela |
| Celltrion USA INC. | $276.26 | 2024-2025 | Vegzelma, Zymfentra |
| Pfizer INC. | $266.28 | 2019-2025 | |
| Janssen Products, LP | $198.99 | 2019-2021 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $176.90 | 2023-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Emd Serono, INC. | $163.76 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $143.22 | 2022-2023 | Quviviq |
| Intercept Pharmaceuticals, INC. | $114.39 | 2019-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $108.50 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.32 | 2023 | Cyltezo |
| Vivus LLC | $107.13 | 2024-2025 | Qsymia |
| Genzyme Corporation | $106.89 | 2023-2025 | |
| Glaxosmithkline, LLC. | $102.54 | 2021 | |
| Endo Pharmaceuticals INC. | $97.17 | 2019-2020 | |
| Lilly USA, LLC | $88.99 | 2024-2025 | Omvoh |
| Organon LLC | $87.41 | 2023-2024 | Hadlima, Renflexis |
| Ironwood Pharmaceuticals, INC | $85.27 | 2019-2024 | |
| Redhill Biopharma INC. | $81.29 | 2021-2024 | Talicia |
| Celgene Corporation | $78.51 | 2023-2024 | Zeposia |
| Daiichi Sankyo INC. | $73.08 | 2019 | |
| Eisai INC. | $72.65 | 2019 | |
| Allergan, INC. | $68.86 | 2019 | |
| Braintree Laboratories, INC. | $51.36 | 2021-2022 | |
| Shire North American Group INC | $47.68 | 2019 | |
| Exact Sciences Corporation | $45.44 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $39.50 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $31.19 | 2025 | Dupixent |
| Shionogi INC | $26.66 | 2021 | |
| Sandoz INC. | $24.55 | 2023 | Hyrimoz |
| Ferring Pharmaceuticals INC. | $18.57 | 2022 | |
| Bavarian Nordic A/S | $18.32 | 2025 | Vivotif |
| Napo Pharmaceuticals INC | $16.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Chun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.